Project Lightspeed: A Case Study in Research Ethics and Accelerated Vaccine Development
Saved in:
| Title: | Project Lightspeed: A Case Study in Research Ethics and Accelerated Vaccine Development |
|---|---|
| Language: | English |
| Authors: | Klaus Leisinger, Doris Schroeder (ORCID |
| Source: | Research Ethics. 2024 20(4):847-856. |
| Availability: | SAGE Publications. 2455 Teller Road, Thousand Oaks, CA 91320. Tel: 800-818-7243; Tel: 805-499-9774; Fax: 800-583-2665; e-mail: journals@sagepub.com; Web site: https://sagepub.com |
| Peer Reviewed: | Y |
| Page Count: | 10 |
| Publication Date: | 2024 |
| Document Type: | Journal Articles Reports - Research |
| Descriptors: | Scientific Research, Research Methodology, Immunization Programs, COVID-19, Pandemics, Ethics, Experimental Programs, Decision Making, Trust (Psychology), Efficiency, Governance, Compliance (Legal) |
| DOI: | 10.1177/17470161241251597 |
| ISSN: | 1747-0161 2047-6094 |
| Abstract: | The COVID-19 pathogen led to a fast expanding pandemic because it proved lethal in certain populations but could be transmitted by persons who appeared healthy. As a result, researchers came under unprecedented time pressure to develop a vaccine. This case study focuses on the first COVID-19 vaccine, which was approved for use in humans, known as Comirnaty, the BioNTech-Pfizer COVID-19 vaccine or Vaccine BNT162b2. With the benefit of hindsight, we show how close collaboration with regulators and trust-based decisions meant that the race for a COVID-19 vaccine was won without purposefully infecting healthy participants with an infectious agent that can cause severe illness or death and for which no rescue therapy had existed. |
| Abstractor: | As Provided |
| Entry Date: | 2024 |
| Accession Number: | EJ1443228 |
| Database: | ERIC |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | The COVID-19 pathogen led to a fast expanding pandemic because it proved lethal in certain populations but could be transmitted by persons who appeared healthy. As a result, researchers came under unprecedented time pressure to develop a vaccine. This case study focuses on the first COVID-19 vaccine, which was approved for use in humans, known as Comirnaty, the BioNTech-Pfizer COVID-19 vaccine or Vaccine BNT162b2. With the benefit of hindsight, we show how close collaboration with regulators and trust-based decisions meant that the race for a COVID-19 vaccine was won without purposefully infecting healthy participants with an infectious agent that can cause severe illness or death and for which no rescue therapy had existed. |
|---|---|
| ISSN: | 1747-0161 2047-6094 |
| DOI: | 10.1177/17470161241251597 |
